312 related articles for article (PubMed ID: 32213066)
1. Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.
Rossi RE; Invernizzi P; Mazzaferro V; Massironi S
United European Gastroenterol J; 2020 Mar; 8(2):140-147. PubMed ID: 32213066
[TBL] [Abstract][Full Text] [Related]
2. Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors.
Allaw MB; Switchenko JM; Khalil L; Wu C; Alese OB; Akce M; Draper A; Jones AT; El-Rayes B; Shaib W
Oncology; 2022; 100(3):131-139. PubMed ID: 35078191
[TBL] [Abstract][Full Text] [Related]
3. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
4. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
5. The safety of lanreotide for neuroendocrine tumor.
Godara A; Siddiqui NS; Byrne MM; Saif MW
Expert Opin Drug Saf; 2019 Jan; 18(1):1-10. PubMed ID: 30582380
[TBL] [Abstract][Full Text] [Related]
6. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
[TBL] [Abstract][Full Text] [Related]
7. Lanreotide delays progression of neuroendocrine tumours.
Gilbert JA
Lancet Oncol; 2014 Sep; 15(10):e418. PubMed ID: 25328940
[No Abstract] [Full Text] [Related]
8. Diagnostic approach to subcutaneous nodules in patients with neuroendocrine tumours treated with depot somatostatin analogs: a cross-sectional study.
Chicharro P; Paniagua A; Rodríguez-Jiménez P; Ibañes S; Cortina B; Riveiro J; Sampedro-Núñez MÁ; Fraga J; Marazuela M; Daudén E
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1887-1892. PubMed ID: 29377286
[TBL] [Abstract][Full Text] [Related]
9. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.
Cives M; Strosberg J
Drugs; 2015 May; 75(8):847-58. PubMed ID: 25911185
[TBL] [Abstract][Full Text] [Related]
10. Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis.
Massironi S; Zilli A; Fanetti I; Ciafardini C; Conte D; Peracchi M
Dig Liver Dis; 2015 Nov; 47(11):978-83. PubMed ID: 26321479
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
12. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
13. Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
Debono M; Hon LQ; Bax N; Blakeborough A; Newell-Price J
J Clin Endocrinol Metab; 2008 May; 93(5):1860-4. PubMed ID: 18303072
[TBL] [Abstract][Full Text] [Related]
14. EVALUATION OF LANREOTIDE DEPOT/AUTOGEL EFFICACY AND SAFETY AS A CARCINOID SYNDROME TREATMENT (ELECT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL.
Vinik AI; Wolin EM; Liyanage N; Gomez-Panzani E; Fisher GA;
Endocr Pract; 2016 Sep; 22(9):1068-80. PubMed ID: 27214300
[TBL] [Abstract][Full Text] [Related]
15. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
[TBL] [Abstract][Full Text] [Related]
16. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
[TBL] [Abstract][Full Text] [Related]
17. Long-acting formulations of somatostatin analogues.
Anthony LB
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S216-8. PubMed ID: 10604134
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
[TBL] [Abstract][Full Text] [Related]
19. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogs in pregnant patients with neuroendocrine tumor.
Meoni G; Giommoni E; Petreni P; Pillozzi S; Mazzoni F; Pellegrini E; Brugia M; Lunghi A; Muto A; Antonuzzo L
Anticancer Drugs; 2020 Nov; 31(10):1096-1098. PubMed ID: 32590392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
